Syndax Pharmaceuticals, Inc. Other Noncash Income (Expense)
Syndax Pharmaceuticals, Inc. (SNDX) reported Other Noncash Income (Expense) of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2024-02-27
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2022-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2020-12-31 was $1.00K.
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2020-09-30 was -$3.00K.
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2021 was $1.00K.
- Syndax Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2020 was -$1.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.00K 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $1.00K 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$2.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$2.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $1.00K 10-Q · filed 2021-08-09 | |||
| 2019-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$2.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $1.00K 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$13.00K derived: sum of 2 quarters · filed 2021-03-12 | -$10.00K derived: sum of 3 quarters · filed 2021-03-12 | -$11.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $2.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.00K 10-Q · filed 2019-11-07 | $1.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $2.00K 10-Q · filed 2019-08-07 | $2.00K derived: sum of 3 quarters · filed 2020-03-05 | $2.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | -$1.00K 10-Q · filed 2019-05-08 | -$1.00K derived: sum of 2 quarters · filed 2020-03-05 | -$1.00K derived: sum of 3 quarters · filed 2020-03-05 | -$2.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | -$1.00K derived: sum of 3 quarters · filed 2020-03-05 | -$8.00K 10-K · filed 2020-03-05 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$1.00K derived: sum of 2 quarters · filed 2018-11-05 | -$8.00K 10-Q · filed 2018-11-05 | |
| 2017-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$8.00K 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | -$7.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$25.00K 10-K · filed 2019-03-07 | |||
| 2015-12-31 | -$8.00K 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $4.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |